For anyone in Fenne looking to source CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. This matters because CJC-1295 quality differs enormously across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor controls every quality variable. A credible CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide walks Fenne researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
The Science Behind CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Fenne comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy CJC-1295 — A Researcher's Guide
Before assessing any particular supplier, establish a quality benchmark — so you can recognise whether a vendor meets it. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. For Fenne researchers evaluating new suppliers: a test quantity before committing to research volumes before placing larger orders is what experienced peptide researchers consistently do. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Fenne
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and restricted human research data. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without visible changes; always maintain cold chain and work with cold-shipped material. The main safety concern arising from sourcing in CJC-1295 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
